Edition:
India

Innoviva Inc (INVA.OQ)

INVA.OQ on NASDAQ Stock Exchange Global Select Market

13.00USD
8 Dec 2017
Change (% chg)

-- (--)
Prev Close
$13.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
247,844
52-wk High
$14.87
52-wk Low
$10.26

Latest Key Developments (Source: Significant Developments)

GSK and Innoviva announce positive data from COPD study
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Glaxosmithkline Plc :GSK STUDY DEMONSTRATES SUPERIORITY OF ANORO ELLIPTA TO STIOLTO RESPIMAT IN IMPROVING LUNG FUNCTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE.GSK - ‍POSITIVE DATA FROM A STUDY COMPARING A ONCE-DAILY LAMA AND LABA FIXED-DOSE COMBINATION, ANORO ELLIPTA AND STIOLTO RESPIMAT FOR COPD​.GSK - ‍ENDPOINT WAS MET, AND UMEC/VI DEMONSTRATED SUPERIORITY TO TIO/OLO, WITH A DIFFERENCE IN TREATMENT EFFECT OF 52ML ON TROUGH FEV1 AT WEEK EIGHT ​.GLAXOSMITHKLINE PLC - ‍MOST FREQUENTLY-REPORTED ADVERSE EVENTS WERE UPPER RESPIRATORY TRACT INFECTIONS, COUGH AND DIARRHOEA​.GLAXOSMITHKLINE PLC - ‍BOTH TREATMENTS DEMONSTRATED A COMPARABLE TOLERABILITY AND SAFETY PROFILE​.GLAXOSMITHKLINE PLC - ‍OVERALL INCIDENCE OF ON-TREATMENT ADVERSE EVENTS OF 25% IN UMEC/VI GROUP AND 31% IN TIO/OLO GROUP​.  Full Article

Innoviva reports Q3 adj earnings $0.31/shr
Thursday, 26 Oct 2017 

Oct 25 (Reuters) - Innoviva Inc :Innoviva reports third quarter 2017 financial results and provides business updates.Q3 adjusted earnings per share $0.31.Q3 earnings per share view $0.31 -- Thomson Reuters I/B/E/S.Innoviva Inc - ‍plans to repurchase up to $80 million of common stock, pursuant to an accelerated share repurchase (ASR) plan​.Innoviva Inc - qtrly ‍total revenue $48.6 million versus $33.3 million.Q3 revenue view $57.2 million -- Thomson Reuters I/B/E/S.  Full Article

GSK presents positive results from phase III FULFIL study
Tuesday, 6 Sep 2016 

GlaxoSmithKline Plc : Gsk presents positive results from phase iii fulfil study of closed triple combination therapy ff/umec/vi versus symbicort® turbohaler® in copd at ers international congress . Study which reported headline results in june 2016, met its two co-primary endpoints .Plans are on schedule for regulatory submissions of closed triple combination therapy for copd in us and europe by end of 2016.  Full Article

Innoviva Q2 adjusted cash earnings per share $0.17
Friday, 29 Jul 2016 

Innoviva Inc : Qtrly total revenue $32.5 million versus $10.7 million . Innoviva reports second quarter 2016 financial results . Q2 adjusted cash earnings per share $0.17 . Q2 earnings per share $0.13 .Q2 earnings per share view $0.11 -- Thomson Reuters I/B/E/S.  Full Article

GlaxoSmithKline says lung drug meets late-stage study goals
Monday, 20 Jun 2016 

Glaxosmithkline Plc : Fulfil study results closed triple eu . Fulfil study shows superiority of closed triple combination therapy ff/umec/vi versus symbicort turbohaler . Data supports regulatory submission by gsk in europe by end of 2016 . Positive top-line results from phase iii study of fluticasone furoate/umeclidinium/vilanterol . Study met its two co-primary endpoints .Study demonstrated statistically significant improvements in lung function and health- related quality of life.  Full Article

Glaxosmithkline and Innoviva report positive headline results in Salford Lung study
Tuesday, 24 May 2016 

Glaxosmithkline Plc : Co and Innoviva announced positive headline results from innovative salford lung study in chronic obstructive pulmonary disease . Study showed that relvar ® ellipta ® 100/25mcg achieved a superior reduction in exacerbations versus usual care, in patients with copd . Analyses remain ongoing and will be subject of future publications and presentations . Second salford lung study is currently being conducted in asthma patients, with results expected in 2017 .For primary effectiveness analysis, in patients treated there was statistically significant reduction in rate of moderate or severe exacerbations.  Full Article

BRIEF-GSK and Innoviva announce positive data from COPD study

* GSK STUDY DEMONSTRATES SUPERIORITY OF ANORO ELLIPTA TO STIOLTO RESPIMAT IN IMPROVING LUNG FUNCTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE